Mepsevii Market Report 2026

Mepsevii Market Overview

• The Mepsevii market growth in the historic period has been driven by limited therapeutic options for mps vii, advancements in recombinant enzyme production • Market expansion is supported by expansion of rare disease treatment pipelines, rising investments in orphan drug development • Growth Driver: Rising Prevalence Of Mucopolysaccharidosis Disorders Boost Market Growth • Market Trend: Launches Of Global Access Expansion Programs Enhance Therapy Availability Worldwide • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mepsevii Market?

Mepsevii (vestronidase alfa) is an enzyme replacement therapy approved for treating Mucopolysaccharidosis VII (MPS VII), a rare genetic disorder. It works by replacing the deficient enzyme beta-glucuronidase, helping to break down harmful substances in the body. It is designed to improve symptoms and quality of life in patients with MPS VII. The main formulations of mepsevii are intravenous infusion and pre-filled syringes. Intravenous infusion is a medical treatment where fluids, medications, or nutrients are directly delivered into the bloodstream through a vein. It is commonly used for administering mepsevii to patients, ensuring the drug reaches the bloodstream efficiently for optimal therapeutic effects. For various indications such as mucopolysaccharidosis VII (MPS VII, sly syndrome). It is distributed through hospitals, specialty clinics, home healthcare services, and pharmacies, and is utilized by end users, including pediatric and adult patients.

What Is The Mepsevii Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of rare disease treatment pipelines, rising investments in orphan drug development, increasing access to genetic testing, growing adoption of home-based infusion services, continued focus on improving patient quality of life. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on ultra-rare genetic disorders, growing demand for long-term disease management solutions, expansion of personalized rare disease treatments, enhanced emphasis on early diagnosis and intervention.

Global Mepsevii Market Segmentation

1) By Formulation: Intravenous Infusion, Pre-Filled Syringes 2) By Indication: Mucopolysaccharidosis VII (MPS VII, Sly syndrome), Enzyme Replacement Therapy 3) By Distribution Channel: Hospitals, Specialty Clinics, Home Healthcare Services, Pharmacies 4) By End User Patients: Pediatric Patients, Adult Patients

What Is The Driver Of The Mepsevii Market?

The increase in the cases of mucopolysaccharidosis disorders is expected to propel the growth of the mepsevii market going forward. Mucopolysaccharidosis (MPS) disorders are a group of genetic diseases caused by the deficiency of specific enzymes that prevent the breakdown of glycosaminoglycans, leading to their accumulation in various organs and causing progressive damage. The increase in the cases of mucopolysaccharidosis (MPS) disorders can be attributed to improved diagnostic techniques, greater awareness among healthcare providers, and better access to genetic testing, leading to earlier and more accurate identification of the disease. Mepsevii helps treat mucopolysaccharidosis VII (MPS VII) by providing enzyme replacement therapy, which replenishes the missing enzyme, beta-glucuronidase. For instance, in March 2024, according to the Oregon Health Authority, a US-based government public health agency, Illinois reported a birth prevalence of 1 in 73,290 for MPS II in 2022, whereas Missouri reported 1 in 96,297 in 2023, demonstrating continued detection of new cases through newborn screening. Therefore, the increase in the cases of mucopolysaccharidosis disorders is driving the growth of the mepsevii industry.

Key Players In The Global Mepsevii Market

Major companies operating in the mepsevii market are Ultragenyx Pharmaceutical Inc

Global Mepsevii Market Trends and Insights

Major companies operating in the Mepsevii market are focusing on launches of expanded global access initiatives, such as vestronidase alfa access-expansion programs, which are structured commercialization efforts that introduce the enzyme-replacement therapy into new countries through reimbursement activation, named-patient pathways, and specialized distribution channels to increase availability for individuals with Mucopolysaccharidosis VII. For instance, in August 2024, Ultragenyx, a U.S.-based biopharmaceutical company, introduced expanded international access efforts for Mepsevii, featuring new territory-specific reimbursement progress, broader geographic distribution enablement, and strengthened rare-disease commercial field teams to support therapy adoption across additional global markets.

What Are Latest Mergers And Acquisitions In The Mepsevii Market?

In December 2024, Cerity Partners LLC, a US-based capital market company, acquired Ultragenyx Pharmaceutical Inc., valued at approximately $1.773 million. Through this acquisition, Cerity Partners LLC gained 31,919 shares of Ultragenyx, aiming to strengthen its investment portfolio by expanding into the biotechnology sector, focusing on companies specializing in rare diseases. Ultragenyx Pharmaceutical Inc. is a US-based biotech company that developed Mepsevii as part of its portfolio of treatments targeting rare genetic conditions.

Regional Insights

North America was the largest region in the mepsevii market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Mepsevii Market?

The mepsevii market consists of sales of mepsevii (vestronidase alfa-vjbk). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mepsevii Market Report 2026?

The mepsevii market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mepsevii industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.